Gland Pharma FDA Inspection 2025 Update

  Published 9 months ago

USFDA inspected Gland Pharma's Visakhapatnam facility (19, 25 Feb 2025), issuing three procedural Form 483s unrelated to data integrity; CAPA submission planned.

  • Gland Pharma operates globally in 60 countries with diverse injectable products.
  • The company pioneered heparin technology in India, expanding its pharmaceutical footprint.
  • Observations are non-repeated; CAPA to be submitted within the stipulated timeline as required by the USFDA.

You might like these

Concord Wins 18‑Month Kavach Rail Safety Order

M&M Group's May 2025 Sales & Exports Surge

Syrma & Dynabook: India Laptop Manufacturing Boost

Indian Stocks Dip Despite Strong Growth

Meson Valves Wins ₹19.89 Cr Order

NTPC Expands Capacity with New 660 MW Unit

Crompton Wins Solar Pumping Order

News that matters the most ⚡